Considering that the presence of mutations in KRAS gene renders tumor cells inherently resistant to anti-EGFR therapy, our results indicate that miR-143 or miR-145 may be key players in mitigating cetuximab resistance in mutant KRAS colon cancer cells. This evidence concerns the gene KRAS and malignant colon neoplasm.